WCG Wealth Advisors LLC Has $2.56 Million Stake in Bristol Myers Squibb Company $BMY

WCG Wealth Advisors LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 154.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,538 shares of the biopharmaceutical company’s stock after purchasing an additional 28,841 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $2,564,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $32,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. Finally, Garner Asset Management Corp acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $35,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $56.71 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a fifty day moving average of $58.13 and a 200-day moving average of $56.52. The firm has a market capitalization of $115.81 billion, a price-to-earnings ratio of 15.93, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the business posted $1.80 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays started coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective on the stock. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Bank of America reduced their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $61.31.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.